Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Size: px
Start display at page:

Download "Chronic Benefit Application Form Cardiovascular Disease and Diabetes"

Transcription

1 Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) Fax: +27 (11) Instructions 1. Complete this application form to register for chronic benefits for the first time or to register an additional chronic condition. 2. Please write in legible capitals and indicate your choice by making a tick ( ) in the appropriate spaces. 3. Complete one application form for each patient requiring chronic benefits. 4. The principal member or patient must complete Sections 1 and 2 in full. 5. The treating doctor must complete Sections 3 to 6 where applicable. 6. If the appropriate sections are not completed, we will not be able to process your application. 7. Attach copies of any reports to support diagnosis of chronic condition, where applicable. 8. Please fax completed forms and results to or to mafricahrm@momentumafrica.com Section 1 - Principal Member Information Member Surname: Initials: Medical Scheme: Membership Number: Option: Section 2 - Patient Information Patient Surname: Initials: Title: First Name(s): Gender: Male Female Date of Birth: Dependant Code: Next of Kin: Postal Address: Postal Code: Contact Numbers: Home Work Cell Phone Fax No: Address Please indicate the method whereby you would prefer to receive your letter of authorisation: Fax Post Provider I hereby give permission for my doctor to provide Momentum Africa with my diagnosis and other relevant clinical information required. I understand that funding from the Chronic benefit is subject to clinical entry criteria and drug utilisation review as determined by the Momentum Africa Disease Management Programme. By registering for the Momentum Africa Disease Management Programme, I am aware that my condition may be subject to periodic review and that this may include access to my medical records and disclosure of general and medical information supplied to Momentum Africa. Generic medication or therapeutic alternatives can significantly reduce prescription costs. Should a generic equivalent be available, this will be authorised in place of your prescribed medication unless your doctor has specified otherwise. If your application to the Momentum Africa Disease Management Programme is declined, the relevant medication can be regarded as acute medication, subject to Momentum Africa Scheme Rules and availability of funds. Signature Date 1 / 5

2 Section 3 - Medical Practitioner Details Surname Initials Type of Practitioner (e.g. general practitioner) Practice No Fax No Tel No Address Signature Section 4 - Risk Assessment To be completed by Doctor Date Height Weight Circumference of waist Relevant Disease Yes No Comments Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Thyroid Disease Abdominal Aortic Aneurysm Nephropathy / Renovascular / Microalbuminuria Dyslipidaemia Angina / Prior Myocardial infarction Cardiac Failure / Valvular Disease Peripheral Vascular Disease Dysrhythmia Hypertension Hypertensive Retinopathy / Other Stroke / Transient Ischaemic Attack Other Procedures Performed Prior CABG Organ Transplant Stent / Angioplasty / Angiogram Please supply details of Family History Lifestyle SMOKING STATUS Smoker Ex-Smoker Non-Smoker LIQUOR INTAKE Daily Weekly Occasionally Never EXERCISE Not Really >3 Hours per Week ALLERGIES (Specify) DETAILS OF HOSPITAL ADMISSIONS IN THE PAST YEAR 2 / 5

3 Cardiovascular Diseases Investigations required: Blood Tests: HB, Random Glukose, Total Cholestrol Urine: Microalbumin / Glukose Resting ECG If required: Stress ECG, Echocardiogram, Renal Ultrasound, Opthalmic Examination, X-ray, 24H Halter ECG Section 5 - Application for Hypertension When did this patient commence drug therapy? Date For hypertension diagnosed in the last six months and all newly diagnosed patients please supply two initial blood pressure readings (before drug therapy commenced) done at least two weeks apart in order to determine the stage of hypertension i) / mmhg Date ii) / mmhg Date Current BP reading (for all patients) / mmhg 24-Hour ambulatory blood pressure monitoring for newly diagnosed patients prior to starting medication, might be required. Section 6 - Application for Hyperlipidaemia Please attach Lipogram - To include total cholesterol, S-HDL, S-LDL, Total Triglyceride. The reimbursement of lipid modifying therapy for primary prevention is reserved for patients with a greater than 20% risk of an acute clinical coronary event in the last 10 years. This funding decision is in accordance with international guidelines. Please risk rate your patient as per the table and indicate your patient's score by circling the appropriate % risk below RISK FACTORS SCORE % RISK FACTORS Age (Years) SCORE WOMEN SCORE MEN SCORE WOMEN SCORE MEN TC (mmol/l) < > HDL-C (mmol/l) < > BP (mmhg) < 120 / / / / > 160/ > > > > 27 > 53 ADD UP RISK SCORES These risk factors should also be considered Obesity Family History Definite diagnosis of F.H. Source: SAMJ February 2000, Vol. 90, No. 2 Drug therapy indicated Smoker 2 2 Diabetic 2 2 Based on the information supplied, does your patient have a 20% or greater chance of a coronary event in the next ten years? We will not fund medication in patients with less than 20% risk of a coronary event in the next ten years. This is a funding decision to ensure the long-term sustainability of this benefit and does not in any way question your clinical decision. 3 / 5

4 Section 7 - Angiotensin-ll-blockers (ARB) Application Please fax the relevant pathology results to confirm the diagnosis of microalbuminuria Which ACE inhibitor(s) did the patient use? Please specify the period of use as well as the strength and dosage. Is the patient intolerant to ACE inhibitors? If the patient is intolerant to ACE inhibitors, which side effects did the patient experience? Please specify and describe the severity of the side effects. Specify which anti-hypertensive medicines, except ACE-inhibitors or angiotensin-ii-blockers, were used previously and indicate the reason why the medicine was discontinued. Please specify the medicine, duration of use, strength and dosage. Does the patient have any of the following diseases? Microalbuminuria (confirmed by three different microalbuminurea: creatinin ratio reports) Left ventricular hypertrophy Chronic renal disease A previous mycardial infarction Coronary artery stenosis Heart failure Please specify the angiotensin-ii-blocker for which you are applying ICD-10 Code Section 8 - Application for Diabetes When did the patient commence drug therapy for diabetes? Please attach the following bloodtests: Random/fasting Bloodglucose Initial fasting insulin HBA1C If Required: GTT For Insulin Resistance - Elevated fasting Insulin and normal glucose: Confirm with KWIK test The following criteria will apply for Diabetes Type 2 Fasting plasma glucose concentration 7mmol/l Casual plasma glucose concentration 1 1.1mmol/l Two hour post glucose or mmol during and Oral Glucose Tolerance Test (OGTT) Please note that based on cost and clinical guidelines, applications for glitazones and nateglinide require a motivation for use over conventional therapy from a specialist physician or endocrinologist. 4 / 5

5 Section 9 - Medication Details Application to register for chronic benefits for the first time or to register an additional condition) Diagnosis ICD10 Code Medication Prescribed Strength Directions For Use Qty per month Repeats other than ongoing Generic alternative Y/N Please state any other medicines taken on a regular basis (including non-prescription, homeopathic or traditional medicines) Please specify any previously approved medicines that must be discontinued and removed from the authorisation schedule Is the patient allergic to or has the patient had an adverse reaction to any medicines? If so, please state names of medicines Please state any conditions such as pregnancy (give due date), porphyria or other conditions treated by other medical practitioners Signature of Medical Practitioner Date Please ensure that the relevant reports and/or test results are included For completion of application form: Claim code / 5

APPLICATION FORM CHRONIC MEDICINE BENEFIT 2019

APPLICATION FORM CHRONIC MEDICINE BENEFIT 2019 APPLICATION FORM CHRONIC MEDICINE BENEFIT 2019 1. Medication for all chronic conditions that are covered may be registered telephonically on 0800 132 345 (doctors and pharmacists only). 2. Alternatively,

More information

SECTION A. PRINCIPAL MEMBER S DETAILS. Cell Fax ( ) SECTION B. PATIENT S DETAILS. Cell Fax ( )

SECTION A. PRINCIPAL MEMBER S DETAILS. Cell Fax ( ) SECTION B. PATIENT S DETAILS. Cell Fax ( ) CHRONIC MEDICINE BENEFIT APPLICATION FORM 2017 (To be used by Nedgroup Hospital, Traditional, Savings and Platinum members only) Please complete the application in black ink One application form must be

More information

Chronic Illness Benefit Application form 2018

Chronic Illness Benefit Application form 2018 Chronic Illness Benefit Application form 2018 Contact us Tel (Members): 0860 99 88 77, Tel (Health partners): 0860 44 55 66, PO Box 784262, Sandton, 2146, www.discovery.co.za. Who we are Discovery Health

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

DAY1 HEALTH CHRONIC MEDICATION BENEFIT APPLICATION FORM

DAY1 HEALTH CHRONIC MEDICATION BENEFIT APPLICATION FORM DAY1 HEALTH CHRONIC MEDICATION BENEFIT APPLICATION FORM Please complete this applica on form as follows: The member of the plan must fill in all personal and membership details in Sec on 1 & 2. Please

More information

HIV MANAGEMENT PROGRAMME APPLICATION FORM

HIV MANAGEMENT PROGRAMME APPLICATION FORM Private Private Bag X82081, Bag X82081, Rustenburg, Rustenburg, 0300 0300 Tel: Tel: (014) 590 5901700 1900 Fax: Fax: 086 (014) 577 0274 591 4570 www.platinumhealth.co.za www.platinumhealth.co.za ZZGPlatinumHealthClinicalMotivation@angloamerican.com

More information

Medical Declaration Form. Important information to read before completing the form:

Medical Declaration Form. Important information to read before completing the form: Administered by Medical Declaration Form Important information to read before completing the form: Pre-Existing Medical conditions Travel insurance only provides cover for emergency medical events that

More information

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors

More information

This Protocol is applicable to Class 1, 2, and Class 3 applicants. Resting ECG shall be performed at the following intervals:

This Protocol is applicable to Class 1, 2, and Class 3 applicants. Resting ECG shall be performed at the following intervals: SCHEDULE 34: PROTOCOL ON ELECTROCARDIOGRAMS ( ECG ) 1. Applicability This Protocol is applicable to Class 1, 2, and Class 3 applicants. 2. Resting ECG Resting ECG shall be perfmed at the following intervals:

More information

The contractor establishes and maintains a register of patients with AF

The contractor establishes and maintains a register of patients with AF Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

Prescribed Minimum Benefits treatment guidelines 2013

Prescribed Minimum Benefits treatment guidelines 2013 Prescribed Minimum Benefits treatment guidelines 20 Treatment guidelines for the Prescribed Minimum Benefit chronic conditions 20 The Chronic Illness Benefit covers a limited number of tests and each for

More information

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Standard Operating Procedure 11 Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Date Version Issue Review Contact Approved Date Date Person October 2013 9 October 2013 March

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

ATTENDING PHYSICIAN'S STATEMENT CORONARY ARTERY BY-PASS SURGERY or OTHER SERIOUS CORONARY ARTERY DISEASE

ATTENDING PHYSICIAN'S STATEMENT CORONARY ARTERY BY-PASS SURGERY or OTHER SERIOUS CORONARY ARTERY DISEASE ATTENDING PHYSICIAN'S STATEMENT CORONARY ARTERY BY-PASS SURGERY or OTHER SERIOUS CORONARY ARTERY DISEASE A) Patient s Particulars Name of Patient Gender NRIC/FIN or Passport No. Date of Birth (ddmmyyyy)

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT PLEASE REMEMBER TO BRING TO EACH APPOINTMENT Conversion table for HbA1c% to mmol/mol Old DCCT aligned HbA1c(%) New IFCC HbA1c (mmol/mol) 4.0 20 5.0 31 6.0 42 6.5 48 7.0 53 7.5 59 8.0 64 9.0 75 10.0 86

More information

CHRONIC MEDICINE BENEFIT APPLICATION FORM

CHRONIC MEDICINE BENEFIT APPLICATION FORM CHRONIC MEDICINE BENEFIT APPLICATION FORM APPLICATION INSTRUCTIONS (please complete this application as follows) 1. The application must be completed in black ink. Please print clearly and legibly. 2.

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

Challenges in type 2 diabetes control: slipping control and weight gain

Challenges in type 2 diabetes control: slipping control and weight gain control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists

More information

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Diabetes Passport. East Coast Area Diabetes Integrated Care

Diabetes Passport. East Coast Area Diabetes Integrated Care Diabetes Passport East Coast Area Diabetes Integrated Care Personal Details Name: Address: Developed by East Coast Area Diabetes Programme (ECAD), 2014. Thanks to Beaumont Hospital for allowing us to use

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE SUMMARY OF CHANGES TO QOF 2018/19 - ENGLAND 18-19 QOF005 KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 17/18 QOF ID 18/19 QOF ID NICE ID Indicator

More information

Prescribed Minimum Benefit Treatment Baskets 2018

Prescribed Minimum Benefit Treatment Baskets 2018 Prescribed Minimum Benefit Treatment Baskets 08 Who are Glencore Medical Scheme (referred to as 'the Scheme"), registration number 5, is a non-profit organisation, registered with the Council for Medical

More information

Sample Submission Form Hypertension in childhood and adolescence

Sample Submission Form Hypertension in childhood and adolescence Sample Submission Form Hypertension in childhood and adolescence Physician Name: Specialty: Clinic / Practice: Street Address: Postal Code: City: Country: Phone: Fax: Email: Patient Information Surname,

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

DVLA Medical Questionnaire

DVLA Medical Questionnaire DVLA Medical Questionnaire Your Name: DOB: Today s Date: 2016 - www.countryhealth.co.uk Contents Introduction Key Client Information Important notes Vision assessment Health questionnaire Nervous system

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence

More information

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 1/17 QOF ID 17/18 QOF ID NICE ID Indicator wording

More information

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Attending Physician Statement- Heart Attack

Attending Physician Statement- Heart Attack Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Heart attack / Cardiomyopathy

More information

How Low Do We Go? Update on Hypertension

How Low Do We Go? Update on Hypertension How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states

More information

Prescribed Minimum Benefit Treatment Baskets for Chronic Disease Baskets of Care 2018

Prescribed Minimum Benefit Treatment Baskets for Chronic Disease Baskets of Care 2018 Prescribed Minimum Benefit Treatment Baskets for Chronic Disease Baskets of Care 08 Who we are SAB Medical Aid (the Scheme), registration number 09, is the medical scheme. This is a nonprofit organisation,

More information

HEART CONDITIONS IN SPORT

HEART CONDITIONS IN SPORT HEART CONDITIONS IN SPORT Dr. Anita Green CHD Risk Factors Smoking Hyperlipidaemia Hypertension Obesity Physical Inactivity Diabetes Risks are cumulative (multiplicative) Lifestyles predispose to RF One

More information

APPENDIX 2F Management of Cholesterol

APPENDIX 2F Management of Cholesterol Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney

More information

Prescribed Minimum Benefit Treatment Baskets- 2018

Prescribed Minimum Benefit Treatment Baskets- 2018 Prescribed Minimum Benefit Treatment Baskets- 08 Who we are The Malcor Medical Aid Scheme (referred to as the Scheme ), registration number 57, is the medical scheme that you a member of. This is a non-profit

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40% Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction

More information

POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK

POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK Author: CHARLOTTE SIMPSON, SPECIALTY REGISTAR PUBLIC HEALTH (ST3), CHESHIRE EAST COUNCIL/MERSEY DEANERY SUMMARY

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison

More information

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

CHALLENGES OF HYPERTENSION IN THE COALFACE

CHALLENGES OF HYPERTENSION IN THE COALFACE CHALLENGES OF HYPERTENSION IN THE COALFACE Y VERIAVA CENTRE FOR RURAL HEALTH SCHOOL OF CLINICAL MEDICINE FACULTY OF HEALTH SCIENCES UNIVERSITY OF WITWATERSRAND SYSTOLIC AND DIASTOLIC BLOOD PRESSURES (BP)

More information

Clinical Practice Guidelines for Diabetes Management

Clinical Practice Guidelines for Diabetes Management Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

From the desk of the: THE VIRTUAL NEPHROLOGIST

From the desk of the: THE VIRTUAL NEPHROLOGIST Hypertension, also referred to as high blood pressure or HTN, is a medical condition in which the blood pressure is chronically elevated. It is a very common illness. One out of three American adults has

More information

Why are NICE guidelines and standards important and relevant to us?

Why are NICE guidelines and standards important and relevant to us? Why are NICE guidelines and standards important and relevant to us? Dr Liz England GP, Laurie Pike health centre RCGP Mental Health Clinical and Commissioning Lead SWB CCG Mental Health Lead NIHR Clinical

More information

5.2 Key priorities for implementation

5.2 Key priorities for implementation 5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail

More information

2013 Hypertension Measure Group Patient Visit Form

2013 Hypertension Measure Group Patient Visit Form Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Page 1. Disclosures. Background. No disclosures

Page 1. Disclosures. Background. No disclosures Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen

More information

Prescribed Minimum Benefit Treatment Baskets 2018

Prescribed Minimum Benefit Treatment Baskets 2018 Prescribed Minimum Benefit Treatment Baskets 08 Who we are LA Health Medical Scheme (referred to as 'the Scheme ), registration number 5, is a non-profit organisation, registered with the Council for Medical

More information

PRESENTED BY BECKY BLAAUW OCT 2011

PRESENTED BY BECKY BLAAUW OCT 2011 PRESENTED BY BECKY BLAAUW OCT 2011 Introduction In 1990 top 5 causes of death and disease around the world: Lower Respiratory Tract Infections Diarrhea Conditions arising during pregnancy Major Depression

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

CARDIAC CT ANGIOGRAM APPOINTMENT FORM AND INSTRUCTIONS

CARDIAC CT ANGIOGRAM APPOINTMENT FORM AND INSTRUCTIONS CARDIAC CT ANGIOGRAM APPOINTMENT FORM AND INSTRUCTIONS Your Cardiac CT Angiogram appointment is:, : am pm (date) (time) (circle one) Please expect to be at your appointment for 1 HOUR. Please call 610-431-5120

More information

Gloucester City Council

Gloucester City Council Gloucester City Council Medical Examination Report To be filled in by the Doctor. The Patient must fill in sections 9 and 10 in the doctor s presence (please use black ink) Before filling in this form,

More information

OPMED APPLICATION FORM FOR Chronic Disease List Conditions (CDL) and other Chronic Conditions

OPMED APPLICATION FORM FOR Chronic Disease List Conditions (CDL) and other Chronic Conditions OPMED APPLICATION FORM FOR Chronic Disease List Conditions (CDL) and other Chronic Conditions ATTENDING MEDICAL PRACTICIONER TO KINDLY COMPLETE THE RELEVANT SECTIONS AND RETURN ALL PAGES TO: PO Box 8796,

More information

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia

More information

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313) University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,

More information

We will only fund Prescribed Minimum Benefit claims should your condition be approved on the Chronic Illness Benefit

We will only fund Prescribed Minimum Benefit claims should your condition be approved on the Chronic Illness Benefit Treatment Baskets for CDL 08 Overview The Prescribed Minimum Benefit Chronic Disease List is a list of conditions which all medical schemes need to on all the plans they offer to their members. This includes

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner 2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current

More information

J-DOIT3 The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases

J-DOIT3 The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases J-DOIT3 The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases A randomized controlled study comparing intensive therapy and conventional therapy in the

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form  Submit request via: Fax Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density

More information

Diabetes Control and Complications in Public Hospitals in Malaysia

Diabetes Control and Complications in Public Hospitals in Malaysia ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,

More information

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High

More information

Case study for CME Diabetes up-to-date management

Case study for CME Diabetes up-to-date management Case study for CME Diabetes up-to-date management Dr Ole Schmiedel, MRCP MD FRACP Physician and Endocrinologist Service Clinical Director Auckland Diabetes Centre GP referral to Auckland Diabetes Centre

More information

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference

More information

Summary of 2011/12 QOF indicator changes, points and thresholds

Summary of 2011/12 QOF indicator changes, points and thresholds Summary of 2011/12 QOF indicator changes, points and thresholds Retirements 2010/11 QOF ID 2010/11 Indicator Wording Points Threshold CHD5 The percentage of patients with coronary heart disease whose notes

More information

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

DIABETES MEASURES GROUP OVERVIEW

DIABETES MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)

More information

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure

More information

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating

More information

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA PRIMARY PREVENTION OF CHD AND STROKE IN HIGH RISK PATIENTS Random non fasting test for total cholesterol, HDL cholesterol (TC:HDL ratio) and LFTs If cholesterol > 7.5 mmol/l or LDL C 5mmol/l exclude secondary

More information

Preventive Cardiology

Preventive Cardiology Preventive Cardiology 21 Volume The Preventive Cardiology and Rehabilitation Prevention Outpatient Visits 7,876 Program helps patients identify traditional and Phase I Rehab 9,932 emerging nontraditional

More information

Heart Disease. Signs and Symptoms

Heart Disease. Signs and Symptoms Heart Disease The term "heart disease" refers to several types of heart conditions. The most common type is coronary artery disease, which can cause heart attack, angina, heart failure, and arrhythmias.

More information

Patient Registration Form

Patient Registration Form Patient Registration Form Date: Last Name: First: Middle: Street Address City State Zip Home Phone: Work Phone: Mobile Phone: Date of Birth: Social Security: Sex: Male Female Martial Status: Single Married

More information

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Personal Diabetes Passport

Personal Diabetes Passport Personal Diabetes Passport Contact information: Name: Physician: Diabetes Education Centre: Dietitian: Ophthalmologist: Chiropodist: Type of Diabetes: Type 1 (T1DM) Increased risk for diabetes Type 2(T2DM)

More information

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the

More information

Ischaemic cardiovascular disease

Ischaemic cardiovascular disease Ischaemic cardiovascular disease What are the PHO performance programme indicators and how are they best achieved? 40 BPJ Issue 36 Supporting the PHO Performance Programme The PHO Performance Programme

More information

ATTENDING PHYSICIAN'S STATEMENT HEART ATTACK / CARDIOMYOPATHY / PERICARDIAL DISEASE / CARDIAC ARRYTHMIA

ATTENDING PHYSICIAN'S STATEMENT HEART ATTACK / CARDIOMYOPATHY / PERICARDIAL DISEASE / CARDIAC ARRYTHMIA ATTENDING PHYSICIAN'S STATEMENT HEART ATTACK / CARDIOMYOPATHY / PERICARDIAL DISEASE / CARDIAC ARRYTHMIA A) Patient s Particulars Name of Patient Gender NRIC/FIN or Passport No. Date of Birth (ddmmyyyy)

More information

Non-Member Health Screening

Non-Member Health Screening Non-Member Health Screening 1390 Taylor Avenue, Winnipeg, Manitoba, R3M 3V8 Phone: 204-488-8023 / Fax: 204-488-4819 Please select Non-Member type: Adult Guest (with member) Adult Guest (without member)

More information

Attending Physician Statement- Coronary Artery Disease / Coronary Artery Surgery

Attending Physician Statement- Coronary Artery Disease / Coronary Artery Surgery Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Coronary artery disease

More information

HeartCheck Questionnaire

HeartCheck Questionnaire July 2018 HeartCheck Questionnaire Please complete pages 2 to 5 before your appointment. You will be asked to complete page 1 in Vhi Medical Centre during your appointment. Page 1 Affix identification

More information